Clinical Trials Logo

Filter by:
NCT ID: NCT01721876 Completed - Clinical trials for Leukemia, Myeloid, Acute

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Start date: January 29, 2013
Phase: Phase 3
Study type: Interventional

To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy

NCT ID: NCT01721746 Completed - Clinical trials for Unresectable or Metastatic Melanoma

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Start date: December 21, 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel

NCT ID: NCT01721161 Completed - Clinical trials for Acute Optic Neuritis

215ON201 BIIB033 In Acute Optic Neuritis (AON)

RENEW
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral Acute Optic Neuritis (AON). The secondary objective of this study in this study population is to assess the safety, tolerability, and pharmacokinetics (PK) of BIIB033.

NCT ID: NCT01721057 Completed - Clinical trials for Rheumatoid Arthritis

A Study in Moderate to Severe Rheumatoid Arthritis Participants

RA-BUILD
Start date: December 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR [inadequate response] participants) and who have not received a biologic disease-modifying antirheumatic drug (DMARD).

NCT ID: NCT01721044 Completed - Clinical trials for Rheumatoid Arthritis

A Moderate to Severe Rheumatoid Arthritis Study

RA-BEACON
Start date: January 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor (TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic drugs (cDMARDs).

NCT ID: NCT01720680 Completed - COPD Clinical Trials

Prospective Exploratory Study to Assess the Effects of the AlphaCore® Device in Patients With COPD

Start date: October 2012
Phase: N/A
Study type: Interventional

- Title: Open-label, prospective exploratory study to assess the effects of the AlphaCore® device on central and peripheral airway dimensions in patients with COPD. - Indication: COPD patients - Study Design: Open-label, prospective design - Study Phase: II - Test treatment duration: 1 day - Test treatment: AlphaCore® device - Dosage regimen: 1 session of stimulation during 90 seconds - Patient number: up to 10 evaluable patients with COPD - Patient age: ≥ 18 years - Sex: male or female - Primary objective: The evaluation of the effect of the AlphaCore® device on central and peripheral airway dimensions with Computational Fluid Dynamics (CFD). - Secondary objectives: The assessment of the effect of the AlphaCore® device on lung function (spirometry, diffusion and resistance) and on patient reported outcomes (PRO`s).

NCT ID: NCT01720524 Completed - Clinical trials for Pulmonary Hypertension, Familial Persistent, of the Newborn

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Start date: August 5, 2013
Phase: Phase 3
Study type: Interventional

This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.

NCT ID: NCT01720381 Completed - Hyperglycemia Clinical Trials

OptiScanner Versus Standard Blood Glucose Monitoring

Start date: July 2012
Phase: N/A
Study type: Observational

The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the Gem 3000, the reference standard for Erasme University Hospital.

NCT ID: NCT01720134 Completed - Clinical trials for Impact of Legislation on Cumulative Delivery Rate

The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.

Start date: September 2010
Phase: N/A
Study type: Observational

Multiple pregnancy (MP) is associated with significant fetomaternal complications and a high cost. The multiple pregnancy rate per cycle (MPR) of treatment with Assisted Reproductive Technology (ART) is 25 % or higher even in countries where ART is reimbursed, much higher than the 1% after natural conception, related to the number of embryos transferred, and preventable by single embryo transfer (SET). In Belgium, the laboratory costs for 6 fresh ART cycles are reimbursed for female patients younger than 43 with a Belgian insurance number since July 2003, but only if a limited number of embryos is transferred depending on female age and cycle rank. Although this policy has resulted in a significant reduction in the MPR after ART in Belgium from 24 % to 13 %, available data are cycle based and it is unknown if the cumulative delivery rate per patient is affected by this legislation. The aim of this study was to test the hypothesis that Belgian ART legislation since 2003, coupling lab reimbursement to restriced embryo transfer policy, has resulted in a reduced CDR when compared to the situation before 2003.

NCT ID: NCT01719718 Completed - Ventral Hernia Clinical Trials

The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair

CLOSURE
Start date: October 2012
Phase: N/A
Study type: Interventional

A multicenter prospective randomized controlled trial comparing closure versus non-closure of the hernia defect between 2 and 5 cm in width using a tissue separating mesh (Physiomeshâ„¢) in laparoscopic ventral hernia repair.